SCHEMBL17780993

SCHEMBL17780993

CC1(C)OC(=O)C(/C=N/c2cccc(OCc3ccccc3)c2)C(=O)O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 0.42
MAOA P21397 4/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
FAAH O00519 1/20 0.40
MGLL Q99685 1/20 0.40
MMP13 P45452 1/20 0.40
ADAMTS5 Q9UNA0 1/20 0.40
NR4A2 P43354 1/20 0.40
GRM5 P41594 1/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39
CCNB1 P14635 1/20 0.39
CCND1 P24385 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.39
LCK P06239 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311212 1.00 MAOB (0.42) MAOBMAOAMEN1KMT2AFAAH
SCHEMBL1959242 0.87 KDM4E (0.46) MAOBMAOAMEN1KMT2AMMP13
SCHEMBL19060472 0.83 MAPK1 (0.35) MAOBMEN1KMT2AKDM4EALDH1A1
SCHEMBL4724622 0.81 MAPT (0.38) MAOBMEN1KMT2ACCNB2CDK1
SCHEMBL10123179 0.79 ALDH1A1 (0.40) MEN1KMT2AKDM4EALDH1A1
SCHEMBL3097423 0.76 GLA (0.52) MAOBMAOAMEN1KMT2AFAAH
SCHEMBL1486473 0.74 FFAR1 (0.46) MAOBMEN1KMT2AFAAHMGLL
SCHEMBL12003807 0.71 ALDH1A1 (0.67) MAOBMAOAMEN1KMT2ANR4A2
SCHEMBL2496071 0.71 MAOB (0.42) MAOBMAOAFAAHMGLLNR4A2
SCHEMBL23838435 0.69 MAOB (0.57) MAOBMAOANR4A2GRM5CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200392110-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2020-12-17 US disclosed
EP-3415501-B9 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2020-12-02 EP disclosed
US-10676462-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2020-06-09 US disclosed
EP-3415501-B1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2020-04-08 EP disclosed
US-10501442-B2 Quinoline derivative ONO PHARMACEUTICALS CO., LTD. (JP) 2019-12-10 US disclosed
US-20190135785-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2019-05-09 US disclosed
US-10208022-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2019-02-19 US disclosed
EP-3415501-A1 QUINOLINE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2018-12-19 EP disclosed
US-20180258072-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2018-09-13 US disclosed
US-9994549-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2018-06-12 US disclosed
US-20170088542-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2017-03-30 US disclosed
US-9573935-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2017-02-21 US disclosed
US-20160168121-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 US disclosed
EP-3026045-A1 QUINOLINE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2016-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392110-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 MAOB 1728/4885MAOA 2085/4885MEN1 1237/4885
US-10501442-B2 Quinoline derivative FLT3, AXL, ERBB2 MAOB 1728/4885MAOA 2085/4885MEN1 1237/4885
US-20180258072-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 MAOB 1728/4885MAOA 2085/4885MEN1 1237/4885
US-10208022-B2 Quinoline derivative FLT3, AXL, ERBB2 MAOB 1728/4885MAOA 2085/4885MEN1 1237/4885
US-20160168121-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 MAOB 1637/4885MAOA 2142/4885MEN1 790/4885
US-20170088542-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 MAOB 1728/4885MAOA 2085/4885MEN1 1237/4885
US-10676462-B2 Quinoline derivative FLT3, AXL, ERBB2 MAOB 1728/4885MAOA 2085/4885MEN1 1237/4885
US-20190135785-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 MAOB 1728/4885MAOA 2085/4885MEN1 1237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.